- Immix Biopharma Inc (NASDAQ:IMMX) announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101).
- In an ongoing Phase 1b study, NXC-201 showed an overall response rate (ORR) of 85% and 71% complete response/stringent complete response (CR/sCR) at the therapeutic dose from the first 20 patients with relapsed/refractory multiple myeloma.
- NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients.
- In addition, zero neurotoxicity of any grade and events of immune effector cell-associated neurotoxicity syndrome (ICANs) were observed.
- Also see: ImmixBio’s Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug.
- Immix Biopharma has formed a wholly-owned subsidiary, Nexcella Inc, to develop and potentially commercialize NXC-201.
- The formation of Nexcella is expected to have a minimal impact on Immix Biopharma’s financial position, as Nexcella, Inc is expected to be an independently financed company.
- “Considering its short 2-day median CRS duration, occurring within a median 1-day post-dosing, we look forward to exploring outpatient administration of NXC-201,” added Gabriel Morris, CFO of Immix Biopharma.
- Price Action: IMMX shares are up 41.08% at $2.07 on the last check Wednesday.
IBM Reports Weak Revenue, Joins Meta Platforms And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Thursday. Shares…
